Free Trial
NASDAQ:EVFM

Evofem Biosciences (EVFM) Stock Price, News & Analysis

Evofem Biosciences logo
$0.0063 +0.00 (+3.28%)
As of 03:52 PM Eastern

About Evofem Biosciences Stock (NASDAQ:EVFM)

Advanced

Key Stats

Today's Range
$0.0058
▼
$0.0066
50-Day Range
$0.0060
▼
$0.0083
52-Week Range
$0.0008
▼
$0.0136
Volume
101,387 shs
Average Volume
198,366 shs
Market Capitalization
$834.94 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evofem Biosciences, Inc. was a commercial-stage biopharmaceutical company focused on developing and providing nonhormonal products for women's sexual and reproductive health. The company was formerly listed on the Nasdaq under the symbol EVFM.

Evofem's principal product was Phexxi, a prescription, nonhormonal vaginal gel designed to prevent pregnancy when used immediately before intercourse. Phexxi was approved by the U.S. Food and Drug Administration in 2020 and was marketed in the United States as an on-demand contraceptive option.

The company also pursued additional products and indications intended to address unmet needs in women's health. Evofem filed for bankruptcy protection in 2022 and subsequently underwent restructuring, after which its public-market status and operations changed. Saundra Pelletier served as the company's chief executive officer during its development and commercialization of Phexxi.

AI Generated. May Contain Errors.

Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVFM Stock News Headlines

Evofem amends key convertible note financing terms
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Evofem Biosciences Inc. (EVFM)
Evofem Biosciences Inc. (EVFM) SEC Filings
See More Headlines

EVFM Stock Analysis - Frequently Asked Questions

Evofem Biosciences' stock was trading at $0.0092 at the start of the year. Since then, EVFM stock has decreased by 31.5% and is now trading at $0.0063.

Evofem Biosciences, Inc. (NASDAQ:EVFM) issued its quarterly earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company had revenue of $5.81 million for the quarter. Evofem Biosciences had a negative net margin of 46.42% and a negative trailing twelve-month return on equity of 91.97%.

Evofem Biosciences's stock reverse split on the morning of Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Vaxart (VXRT), Palantir Technologies (PLTR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
6/16/2023
Today
11/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:EVFM
CIK
1618835
Employees
29
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
($0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$52.98 million
Net Margins
-46.42%
Pretax Margin
-46.42%
Return on Equity
-91.97%
Return on Assets
-61.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.11
Quick Ratio
0.09

Sales & Book Value

Annual Sales
$11.39 million
Price / Sales
0.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.64) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
132,530,000
Free Float
113,118,000
Market Cap
$834.94 thousand
Optionable
Not Optionable
Beta
-1.41

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:EVFM) was last updated on 11/4/2026 by MarketBeat.com Staff.
From Our Partners